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Ror2-mediated alternative Wnt signaling regulates cell fate and
adhesion during mammary tumor progression
K Roarty1, AD Pfefferle2, CJ Creighton3, CM Perou2 and JM Rosen1
Cellular heterogeneity is a common feature in breast cancer, yet an understanding of the coexistence and regulation of various
tumor cell subpopulations remains a significant challenge in cancer biology. In the current study, we approached tumor cell
heterogeneity from the perspective of Wnt pathway biology to address how different modes of Wnt signaling shape the behaviors
of diverse cell populations within a heterogeneous tumor landscape. Using a syngeneic TP53-null mouse model of breast cancer,
we identified distinctions in the topology of canonical Wnt β-catenin-dependent signaling activity and non-canonical β-catenin-
independent Ror2-mediated Wnt signaling across subtypes and within tumor cell subpopulations in vivo. We further discovered an
antagonistic role for Ror2 in regulating canonical Wnt/β-catenin activity in vivo, where lentiviral shRNA depletion of Ror2 expression
augmented canonical Wnt/β-catenin signaling activity across multiple basal-like models. Depletion of Ror2 expression yielded
distinct phenotypic outcomes and divergent alterations in gene expression programs among different tumors, despite all sharing
basal-like features. Notably, we uncovered cell state plasticity and adhesion dynamics regulated by Ror2, which influenced Ras
Homology Family Member A (RhoA) and Rho-Associated Coiled-Coil Kinase 1 (ROCK1) activity downstream of Dishevelled-2 (Dvl2).
Collectively, these studies illustrate the integration and collaboration of Wnt pathways in basal-like breast cancer, where Ror2
provides a spatiotemporal function to regulate the balance of Wnt signaling and cellular heterogeneity during tumor progression.
Oncogene (2017) 36, 5958–5968; doi:10.1038/onc.2017.206; published online 26 June 2017
INTRODUCTION
The advent of high-throughput molecular profiling has helped
classify breast cancers into distinct subtypes by global gene
expression-based approaches. These ‘intrinsic’ subtypes include
Luminal A, Luminal B, Her2-enriched, basal-like, claudin-low and
normal-like, and complement classical pathology to reveal
distinctions in breast cancer incidence, survival and treatment
responses.1–3 Triple negative breast cancers lack expression of
estrogen and progesterone receptors (ER and/or PR) and
amplification of epidermal growth factor receptor 2 (Her2), and
are further divided into the basal and claudin-low subtypes.4,5
Notably, breast cancer subtypes reflect differentiation states of the
normal epithelial hierarchy, spanning cell states that reflect the
multipotent stem cell down to fully differentiated ER+ luminal
cells.6 The basal-like and claudin-low subtypes are suggested to
reflect the less-differentiated luminal progenitor and mammary
stem cell states, respectively, with claudin-low tumors exhibiting
more mesenchymal-like characteristics.7 Considerable evidence
now suggests that while global gene expression-based
approaches capture the intertumoral heterogeneity between
individual tumors and subtypes, these approaches fail to resolve
the cellular diversity present within individual tumors. Indeed,
more refined molecular analyses now demonstrate considerable
genetic and phenotypic variations within tumors, where vast
intratumoral cellular hierarchies exist.8
Wnt signals are categorized by their ability to either stabilize
β-catenin in the nucleus (canonical/β-catenin-dependent) or elicit
alternative routes of intracellular signaling independent of
β-catenin stabilization (non-canonical/β-catenin-independent).9
Canonical Wnt signaling controls numerous biological processes
that include cell fate determination, self-renewal and tissue
homeostasis.10 Non-canonical Wnt signals regulate organized
cellular movements, cell shape and the orientation of proper cell
polarity in development.11,12 A canonical or non-canonical Wnt
signaling outcome within a cell depends, in part, on the receptor
context.12–14 Canonical Wnt signaling utilizes Frizzled receptors
(Fzd) together with co-receptors low-density lipoprotein-related
receptor proteins 5/6 (Lrp5/6) to stabilize intracellular β-catenin
and transcriptional activation of T-cell factor/Lymphoid enhancer-
binding factor (Tcf/Lef)-dependent outputs, while non-canonical
Wnt signals require Fzd receptors independent of Lrp5/6 and/or
utilize the alternative Wnt receptors Ror1, Ror2 or Ryk. Alternative
Wnt receptors are implicated in conveying a Wnt5a signal;
however, Ror2 represents a favored receptor candidate of non-
canonical Wnt5a signaling due to similarities in spatiotemporal
expression across tissues and overlap between loss-of-function
mutants.15–18 While less defined, alternative Wnt outputs down-
stream of Ror2 include Rho and Rac GTPases, c-Jun N-terminal
kinase (JNK), the calcium-sensitive kinases calmodulin-dependent
protein kinase (CAMKII) and protein kinase C (PKC), and nuclear
factor of activated T cells (NFAT).9,11 The ability of non-canonical
Wnt signaling to inhibit the canonical Wnt pathway in some
contexts emphasizes the cross talk and lack of linearity between
pathways. Deciphering this integration remains an unresolved task
both in development and disease.
Activating mutations within the Wnt pathway are infrequent in
breast cancer;19 however, hyperactivated levels of canonical Wnt
signaling exist within basal-like breast cancers.20–22 Studies also
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demonstrate a role for non-canonical Wnt signaling in breast
cancer, with either negative or positive correlations regarding
clinical outcome, involving a variety of alternative Wnt signaling
constituents that include Vangl,23 Fzds,24 Rors25,26 and individual
Wnts.27,28 The broad spectrum of non-canonical Wnt signaling
mechanisms and diverse receptor repertoires complicate the
assignment of generalized roles for alternative Wnt signaling in
breast cancer. An outstanding challenge is to decipher how inter-
and intratumoral heterogeneity factor into the equation when
considering the Wnt signaling landscape and the integration of
multiple arms of Wnt signaling within a tumor.
In the current study, we utilize a transplantable syngeneic TP53-
null genetically engineered mouse model of breast cancer to
interrogate the function of the alternative Wnt receptor Ror2 in
breast cancer. We establish the integration of Wnt pathways
within basal-like TP53-null tumors and an inverse correlation
between Wnt β-catenin-dependent and -independent pathways
among tumor cell subpopulations. Furthermore, we identify
context-dependent functions for Ror2 with respect to tumor
heterogeneity, and uncover unique nodes of signaling down-
stream of Ror2 which regulate plasticity, cell fate and cell–cell
interactions within the tumor landscape.
RESULTS
Assessment of Wnt/β-catenin-dependent activity and expression
of the alternative Wnt receptor Ror2 uncovers the presence of
inter- and intratumoral heterogeneity within the TP53-null
mammary tumor model
We utilized a collection of transplantable mammary tumors
representing characteristics of human breast cancer with respect
to histology, gene expression programs and subtype, derived from
the TP53-null genetically engineered mouse model,29–31 to assess
the integration of Wnt/β-catenin-dependent and -independent
pathways in vivo. Using a subset of these models representing
luminal, basal-like and claudin-low subtypes, we first examined
the Wnt pathway landscape across heterogeneous TP53-null
models. By transduction of tumor cells with a lentiviral reporter
harboring a 7xTCF/Lef responsive promoter upstream of eGFP,32
we observed that only basal-like TP53-null tumors (T1, T2, 2225L)
harbored canonical Wnt-active cell populations relative to luminal
and claudin-low tumors, similar to that observed in human breast
cancers (Figure 1a).21,22,33 Within TP53-null tumors with intrinsic
Wnt activity, we also detected expression of the alternative Wnt
receptor Ror2, a mediator of non-canonical Wnt signaling
(Figures 1b–g). Although Wnt/β-catenin-dependent pathway
activity was restricted to basal-like tumors, we observed varying
levels of Ror2 expression in all subtypes of the TP53-null model,
supporting context-dependent functions for Wnt/β-catenin-inde-
pendent signaling within specific subtypes (Figure 1b). Upon
closer examination of basal-like tumors, we identified prevalent
expression of Ror2, with a heterogeneous and graded expression
pattern, often distinct from cell populations harboring an active
canonical Wnt/β-catenin-dependent signal based on 7xTCF-eGFP
reporter activity in vivo (Figures 1c and d). As opposed to the
normal mammary epithelium,34 some overlap of Ror2 expression
with Wnt/β-catenin-dependent activity was detected within the
TP53-null tumors, demonstrating lack of complete mutual
exclusivity (Figures 1d–g). Interestingly, we identified a negative
correlation between Ror2 expression and an active canonical Wnt
signature across human breast tumors in the TCGA database
(Figure 1h). These results were further validated in human breast
tumors of the basal-like subset (Figure 1i), suggesting that Wnt/β-
catenin-independent signaling through Ror2 may function as a
cellular rheostat to control levels of Wnt/β-catenin-dependent
activity within the tumor landscape.
Depletion of Ror2 expression in basal-like TP53-null models
impairs tumor growth and enhances canonical Wnt signaling
across basal-like TP53-null models despite distinctions in both
histopathology and gene expression outcomes
Given the co-occurrence of Ror2 expression with decreased Wnt/
β-catenin signaling activity in basal-like TP53-null models, we used
a lentiviral shRNA approach to deplete Ror2 in vivo and investigate
effects on both the canonical Wnt landscape and tumor
progression. Interestingly, Ror2 knockdown (Figure 2a) impaired
tumor growth relative to controls that harbored a nonspecific
hairpin (Figures 2b–d). Importantly, expression of Ror1, a second
Ror family member possessing 56% amino acid homology with
Ror2,35 was not impacted upon Ror2 knockdown (Supplementary
Figures S1a and b). Ror2-depleted tumors exhibited a decrease in
proliferation assessed by BrdU incorporation across T1 (Figures 2e
and f), T2 (Figures 2h and i) and 2225L (Figures 2k and l) models,
with no statistically significant changes observed in apoptosis
(Figures 2g, j and m).
Co-transduction of tumors with the 7xTCF-eGFP Wnt reporter
revealed that Ror2-depleted tumors displayed an increase in the
percentage of cells harboring canonical Wnt/β-catenin-dependent
activity, suggesting that depletion of Ror2 abrogated the
inhibition of canonical Wnt signaling in vivo (Figure 3a). Con-
versely, lentiviral overexpression of Ror2 above endogenous levels
enhanced the antagonism of canonical Wnt signaling in vivo
(Supplementary Figures S2a–c). Although Ror2 loss enhanced
canonical Wnt signaling across all basal-like tumor models
(Figure 3a), other phenotypic outcomes were distinct. For
example, histological examination of tumors revealed squamous
differentiation present in T1 and T2 models upon Ror2 loss,
previously observed in other GEM and PDX models with
hyperactive Wnt signaling (Figure 3b and Supplementary
Figure S1c).36–39 Loricrin, a late epidermal differentiation marker,
was expressed within areas exhibiting elevated 7xTCF-eGFP
activity and squamous features within T1 (Supplementary
Figures S1d and e). However, depletion of Ror2 in 2225L yielded
a more disorganized tumor architecture and increase in stroma,
with no squamous differentiation evident (Figure 3b and
Supplementary Figure S1c).
Differences in histological outcomes despite a common trend in
elevated Wnt/β-catenin-dependent activity upon Ror2 loss
prompted a global assessment of gene expression alterations by
microarray between shLUC and shRor2 tumors among basal-like
models. Microarray analysis of sorted, lineage-depleted tdTomato-
positive shLUC and shRor2 tumor cell populations failed to resolve
a prominent Ror2 gene signature across models, but revealed
distinct gene expression signatures in response to Ror2 depletion
(Figure 3c). These differences were confirmed when assessing the
overlap in up- and downregulated genes shared between models
upon Ror2 depletion, with very few genes similarly changed across
all three models (Figures 3d and e and Supplementary Figures S3a
and b). Gene ontology (GO) enrichment analysis revealed cellular
motifs including immune response, cell adhesion and epidermis
development for T1 (Figure 3f); response to wounding, epidermis
development, metabolism and cell adhesion for T2 (Figure 3g);
and cell migration, biological adhesion and cellular morphogen-
esis for 2225L (Figure 3h). These data, therefore, uncovered
unexpected context-dependent functions for Ror2 during mam-
mary tumor progression, despite all models being designated as
basal-like.
Loss of Ror2 expression in vivo results in changes in tumor cell
plasticity between basal-like and claudin-low states
The presence of a strong cell adhesion and migration GO
signature upon Ror2 depletion in 2225L prompted a more
detailed investigation of Ror2 function within this model, given
the role of non-canonical Wnt signaling in mediating cell
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adhesion, morphogenesis and polarity. Although gene expression
profiling of the bulk 2225L TP53-null tumors categorized them as
basal-like, further refinement of this model using flow cytometry
for cell surface markers CD24 and CD29 resolved two distinct cell
populations: a bulk CD24+CD29+ population and minor CD24neg
CD29+ population comprising ~ 5% of the tumor (Figure 4a). By
gene expression profiling, these two populations clustered into
distinct CD24+CD29+ basal-like and CD24negCD29+ claudin-low
populations, similar to that observed in human cell lines.40
Intriguingly, when assessing expression of Ror2 and other Wnt
receptors and ligands, we discovered that the basal-like and
claudin-low populations harbored differences in Wnt pathway
components. Of note, Ror2 expression was similar across the two
populations (Figure 4b). Conversely, the Lrp5 co-receptor for Wnt/
Figure 1. Assessment of canonical Wnt activity and Ror2 expression uncovers the complex coexistence of Wnt pathways in TP53-null mouse
models and human breast cancer. (a) The percentage of canonical Wnt-active cells in basal-like TP53-null tumors relative to luminal and
claudin-low, based on fluorescence-activated cell sorting (FACS) analysis of tumors harboring a lentiviral Wnt reporter with a 7xTCF responsive
promoter upstream of eGFP. FACS percentages for basal-like tumors: T1 (31.0± 6.1%, n= 3 tumors), T2 (50.9± 2.5%, n= 3 tumors) and 2225L
(24.6± 9.8%, n= 3 tumors). (b) Western blot for Ror2 in a panel of TP53-null tumors representing luminal, basal-like and claudin-low subtypes.
(c) Immunohistochemistry for Ror2 within T1, T2 and 2225L basal-like TP53-null models depicting a spectrum of Ror2 positivity within each
basal-like model. Scale 50 μm. (d) Co-immunofluorescence for Ror2 (green) and 7xTCF-mCherry (red), demarcating active canonical Wnt
activity, across three TP53-null basal-like models. Scale 50 μm. (e–g) Quantitation of immunofluorescence staining of mCherry positive (7xTCF
responsive) Wnt populations within Ror2-negative and Ror2-positive populations within basal-like tumors (e) T1 (43.7± 4.4% in Ror2-neg vs
7.3± 2.1% in Ror2-pos tumor cells, n= 6 tumors), (f) T2 (53.5± 14.14% in Ror2-neg vs 10.2± 1.7% in Ror2-pos tumor cells, n= 6 tumors) and (g)
2225L (24± 8.2% in Ror2-neg vs 2.2± 1.3% in Ror2-pos tumor cells). (h) Scatter plot of individual human breast tumors within the TCGA
database illustrating an inverse correlation between Ror2 expression and an active canonical Wnt signature (Spearman rank correlation,
n= 1095 cases, correlation coefficient: − 0.26, one-sided Po1× 10− 17). (i) Scatter plot of human breast tumors of the basal-like subtype within
TCGA demonstrating an inverse correlation between Ror2 expression and an active canonical Wnt signature (Spearman rank correlation, 122
cases, correlation coefficient: − 0.32, one-sided Po0.0005).
Ror2 regulates plasticity and adhesion during tumor progression
K Roarty et al
5960
Oncogene (2017) 5958 – 5968
β-catenin-dependent signaling showed enrichment within the
basal-like relative to claudin-low populations (Figure 4b), while
some Wnt ligands showed enrichment within either basal-like
(Wnt5b, Wnt6, Wnt7b, Wnt10a, Wnt10b) or claudin-low (Wnt5a,
Wnt11) subpopulations, with neutral expression patterns present
as well (Wnt4) (Figure 4c). These data suggest distinct subpopula-
tions of tumor cells likely utilize Wnt signals in a refined manner to
shape-specific cellular interactions and outcomes related to cell
fate and coordinated movements, much like the normal
mammary gland.
Interestingly, loss of Ror2 within 2225L resulted in a four-fold
expansion of the claudin-low CD24negCD29+ population, revealing
a shift in the cellular composition within the tumors (Figures 4d
and e). This increased proportion of claudin-low to basal tumor
cells was additionally reflected by gene expression profiling of
shLUC and shRor2 tumors, where a claudin-low gene signature
was enriched upon Ror2 loss (Figure 4f). Specifically, expression
analysis of control versus Ror2-depleted tumors confirmed that
genes upregulated in shRor2 tumors were associated with claudin-
low features, while genes downregulated were associated with
Figure 2. Lentiviral silencing of Ror2 expression in basal-like TP53-null models impairs tumor growth. (a) Western blots for Ror2 illustrating
shRNA depletion of Ror2 protein levels with two independent hairpins in T1, T2 and 2225L TP53-null basal-like models. GAPDH protein depicts
equal loading between samples. (b–d) Tumor growth curves representing changes in tumor volume over time (days) for (b) T1, (c) T2 and (d)
2225L, comparing changes in tumor volume between shLUC control tumors and shRor2 tumors (n= 6 tumors within each group,
***Po0.001). Volumes were calculated using the formula, volume= (length ×width2)/2. (e,f,h,i,k,l) Proliferation of shLUC vs shRor2 tumors
based on BrdU incorporation. (e,h,k) Representative immunofluorescence images of BrdU-positive cells (green) among transduced tumor cells
(red) between shLUC and shRor2 groups within (e) T1, (h) T2 and (k) 2225L. Scale 50 μm. (f,i,l) Quantitation of BrdU-positive cells (green)
among transduced tumors cells (red) between shLUC and shRor2 groups among (f) T1 (shLUC 19.4± 4.2% vs shRor2 12.6± 2.5%, n= 6
**Po0.01), (i) T2 (shLUC 30.1± 3.6% vs shRor2 9.1± 3.8%, n= 6, ***Po0.001), (l) 2225L (shLUC 26.1± 3.9% vs shRor2 13.0± 2.4%, n= 6,
***Po0.001). (g,j,m) Quantitation of apoptosis, CC3 positivity, among transduced tumor cells between shLUC and shRor2 groups among (g)
T1 (shLUC 1.0± 0.4% vs shRor2 3.5± 3.2%, n= 6), (j) T2 (shLUC 0.90± 0.52% vs shRor2 1.5± 0.50%, n= 6) and (m) 2225L (shLUC 0.80± 0.65% vs
shRor2 0.96± 0.47%, n= 6).
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basal-like features (Figure 4f), reflecting the shift in balance of
tumor cell subsets and change in Wnt signaling landscape across
tumors.
Impaired Ror2 signaling enhances tumor cell migration by altering
cytoskeletal and adhesion dynamics
The fact that claudin-low breast cancers lack tight junctions and
possess features of an epithelial-to-mesenchymal transition was
intriguing when considering certain features identified in shRor2
2225L tumors, particularly the enriched cell adhesion and
migration gene signature and histological features that indicated
a less organized tumor landscape. As a surrogate assay, we
developed three-dimensional models of lentivirus-infected tumor
organoids for short-term phenotypic assessment, harboring shLUC
and shRor2 hairpins, to recapitulate Ror2-intact versus -depleted
tumors. Within the 2225L TP53-null basal-like organoid model,
depletion of Ror2 conferred a pro-migratory phenotype,
Figure 3. Depletion of Ror2 expression enhances canonical Wnt signaling across basal-like TP53-null models despite distinctions in both
histopathology and gene expression outcomes. (a) Elevated Wnt/β-catenin signaling occurs in the absence of Ror2 in all three basal-like TP53-
null models. Quantitation of fluorescence-activated cell sorting analysis of 7xTCF-eGFP positivity within shLUC and shRor2 tumors within T1,
T2 and 2225L models (n= 3 shLUC tumors and n= 3 shRor2 tumors per basal-like model, *Po0.05, **Po0.001). (b) H&E staining of shLUC and
shRor2 tumors showing squamous differentiation in T1 and T2 and disorganization in 2225L upon Ror2 loss. Scale 50 μm. (c) Supervised
clustering and heat map showing gene expression changes (Po0.01 by t-test, fold change41.4) across TP53-null basal-like models T1, T2 and
2225L, harboring shLUC vs shRor2 hairpins (derived from sorted transduced tdTomato-positive tumor cells). Within each model (T1, T2,
2225L), expression values were centered on the corresponding control. Bright yellow/blue represents minimum of two-fold change from the
corresponding control. (d, e) Venn diagrams of (d) upregulated and (e) downregulated genes represented in shLUC and shRor2 groups within
T1, T2 and 2225L, illustrating gene expression overlap between basal-like TP53-null models in response to Ror2 depletion. (f–h) Gene ontology
analysis illustrating the enrichment of particular gene expression programs within (f) T1, (g) T2 and (h) 2225L.
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accompanied by more protrusive cellular fronts along with
disseminated clusters of cells into the surrounding matrix
(Figures 5a and b). T1 and T2 tumor organoids, on the other
hand, lacked any evidence of invasive outcome in vitro and
recapitulated the squamous phenotype upon Ror2 loss, marked by
the presence of keratin pearls within the centers of shRor2
organoids (Supplementary Figures S4a and b). Within 2225L
organoids, Keratin-8 (K8) and -5 (K5) cells, demarcating luminal
and basal cell identities, respectively, were similarly heteroge-
neous between shLUC and shRor2 groups (Figure 5c). Since
cytoskeletal defects were evident upon Ror2 loss in normal
mammary development, we examined the distribution of F-actin
in 2225L organoids by phalloidin staining. Of note, changes in
cortical F-actin patterns were evident in shRor2 organoids relative
to controls, where irregularities in cortical F-actin continuity were
observed along with F-actin projections into the surrounding
matrix (Figure 5d, shLUC magnified d′ and shRor2 d″). Additionally,
the distribution of phosphorylated-Ezrin/Radixin/Moesin (pERM), a
protein family necessary in crosslinking the actin cytoskeleton and
plasma membrane, was discontinuous between cell–cell junctions
in shRor2 organoids versus shLUC organoids, where a continuous
pattern of pERM staining was evident (Figure 5e, magnified shLUC
e′ and shRor2 e″). Indeed, other genes associated with junction
integrity, such as desmocolin and desmoglein, were
downregulated within shRor2 tumors. Collectively, these data
suggest that alterations in cytoskeleton dynamics and a loss of
cellular adhesion occur upon Ror2 loss in 2225L tumors.
The Rho family of GTPases, a key mediator of actin cytoskeletal
rearrangements and cell adhesion/migration cues, represents an
important signaling hub downstream of Wnt/β-catenin-indepen-
dent signaling in many developmental contexts responsible for
orientation of cell polarity and morphogenesis.41 Interestingly,
RhoA and Rho-Associated Coiled-Coil Containing Protein Kinase 1
(ROCK1) protein expression were downregulated in shRor2 2225L
organoids relative to shLUC organoids, while CDC42 and Rac1/2/3
levels were unchanged (Figure 5f). Additionally, expression of p-c-
Jun (Ser63) was reduced upon Ror2 depletion, suggesting a
potential RhoA→ ROCK1→ JNK→ c-Jun signaling cascade
mediated by Ror2 to control tumor intercellular interactions and
adhesive states during tumor progression (Figure 5f). Administra-
tion of a ROCK inhibitor, Y-27632, to 2225L organoids similarly
resulted in organoids that exhibited disorganization and invasive
fronts into the surrounding matrix, partially phenocopying Ror2-
depleted organoids (Figures 5g and h). Of note, neither T1 nor T2
organoids showed changes in the expression of proteins within
the Rho-GTPase and JNK pathways, suggesting divergent signal-
ing outputs downstream of Ror2 across basal-like models
(Supplementary Figures S4c and d).
Figure 4. shRNA depletion of Ror2 expression in vivo results in changes in tumor cell plasticity between basal-like and claudin-low
subpopulations in the 2225L TP53-null model. (a) Representative fluorescence-activated cell sorting (FACS) plot depicting the segregation of
2225L tumors into two distinct populations based on CD24 and CD29 cell surface marker staining. (b) Quantitative real-time PCR of Ror2 and
Lrp5 within sorted basal-like and claudin-low fractions from 2225L. (c) Quantitative real-time PCR of Wnt ligands within sorted basal-like and
claudin-low subpopulations within 2225L. (d) FACS plots of shLUC and shRor2 tumors stained with CD24 and CD29, illustrating the shift in
tumor cell populations upon Ror2 loss, from basal-like to claudin-low. (e) Quantitation of basal-like and claudin-low populations within shLUC
and shRor2 2225L TP53-null tumors (shLUC basal-like 93.4± 1.2% claudin-low 4.97± 0.7% vs shRor2 basal-like 80.3± 1.6% claudin-low
18.2± 1.2%, n= 5). (f) Box plots depicting gene expression signatures across subtypes represented in shRor2 vs shLUC tumors. Genes
upregulated in shRor2 2225L tumors are associated with claudin-low features. Genes downregulated are associated with basal-like features
(red boxes).
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This divergence likely occurs either at the same level, or
downstream, of the molecular hub of Wnt signaling, Dishevelled
(Dvl). Specifically, we identified a decrease in the phosphorylated
form of Dvl2 in shRor2 2225L organoids evident as the slower
mobility band in western blot (Figure 5f). Impaired Ror2 function
in T2 organoids similarly resulted in a decline in p-Dvl2
(Supplementary Figure S4d); however, T2-associated phenotypes
were likely from alternative modes of signaling downstream of
Dvl2, given the lack of apparent change in Rho-GTPase and JNK
pathways as in 2225L. Moreover, Ror2-depleted T1 organoids
exhibited a Dvl2-independent phenotype, with no change in
p-Dvl2 (Supplementary Figure S4c). Collectively, these results
implicate the Rho-GTPase and JNK pathways downstream of Ror2
in 2225L TP53-null tumors in mediating appropriate cytoskeleton
and adhesive cues among tumor cells. The presence of
intertumoral heterogeneity, as seen for other basal-like models
T1 and T2, highlight the importance of cellular context in
interpreting broad functions for alternative Ror2 signaling in
breast cancer. Furthermore, these studies, using three indepen-
dent TP53-null genetically engineered mouse models, illustrate
the considerable heterogeneity reported for basal-like breast
cancers within subgroups5 and the complex coexistence of tumor
cell subpopulations during tumor progression.42,43
DISCUSSION
Our results revealed that tumor heterogeneity and cellular context
considerably influence the Wnt pathway output during tumor
progression. In particular, we demonstrated that expression of the
alternative Wnt receptor Ror2 resides in multiple TP53-null breast
tumor models across luminal, basal-like and claudin-low subtypes,
whereas Wnt/β-catenin-dependent signaling was preferentially
restricted to the basal-like TP53-null subtype. While it is
appreciated that a hyperactivated Wnt pathway exists in basal-
like breast cancers,20–22 we discovered that Ror2 expression is
negatively correlated with Wnt/β-catenin-dependent pathway
activity within the intratumoral landscape of basal-like TP53-null
tumor models and across human breast tumor samples within the
TCGA. We further showed that Ror2 expression modulation by
lentiviral-mediated shRNA silencing influences the level of
Figure 5. Three-dimensional modeling of tumor organoids reveals alterations in cytoskeletal and adhesion dynamics upon Ror2 loss.
(a) Brightfield DIC images showing enhanced migration of shRor2 organoids into the surrounding matrix. Scale 50 μm. (b) Quantitation of
cellular protrusions emanating into the surrounding matrix in shLUC vs shRor2 organoids (***Po0.001, n= 63 organoids per shLUC and
shRor2 group). (c) Immunofluorescence of shLUC and shRor2 organoids for K8 (red) and K5 (green). Scale 50 μm. (d) Phalloidin staining and
Maximum Intensity Projection of shLUC and shRor2 organoids demonstrating alterations in F-actin dynamics upon Ror2 loss. Scale 50 μm. (d′)
Magnified slice of shLUC organoid within (d) depicting cortical F-actin staining at cell junctions in shLUC 2225L organoids. (d″) Magnified slice
of shRor2 organoid within (d) illustrating the change in patterning of F-actin and presence of F-actin projections within protrusive nodes of
shRor2 organoids (arrows). Scale 10 μm. (e) Immunofluorescence of pERM (green), K8 (red) and nuclei (blue), showing changes in pERM upon
Ror2 loss. Scale 50 μm. (e′) Magnified shLUC pERM staining. (e″) Magnified shRor2 pERM staining. Scale 25 μm. (f) Western blot of 2225L shLUC
vs shRor2 organoids for Ror2, p-Dvl2, Dvl2, RhoA, CDC42, Rac1/2/3, ROCK1, p-c-jun S63 and c-jun. (g) Representative brightfield DIC images of
shLUC vs shRor2 organoids after administration of Y-27632, a ROCK inhibitor (50 μM). Scale 50 μm. (h) Quantitation of the number of invasive
nodes per organoids between control and ROCK inhibitor-treated organoids after 3 days (***Po0.001, n= 30 organoids per shLUC and shRor2
group).
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Wnt/β-catenin-dependent signaling in vivo by diminishing this
antagonism. Thus, in the context of tumor heterogeneity, a tumor
cell’s expression of Ror2 regulates the spatial distribution, duration
and amplitude of canonical Wnt signaling within a tumor,
depending on the repertoire of Wnt signaling components
present. In hematopoiesis and other developmental systems, the
particular dosage of canonical Wnt signaling is critical with respect
to dictating lineage specification and cellular output.44,45 In the
current study, the balance of Ror2 expression coupled with Wnt/β-
catenin-dependent pathway activity within the tumor represents
an important factor in tumor progression. Whether these
gradients of expression denote a hierarchy of cellular differentia-
tion within the tumor or influence cellular plasticity remains to be
determined; however, breast cancers likely harbor Wnt signaling
gradients that supply spatiotemporal and contextual cues for
tumor cells during progression and metastasis, as has been
observed in many developmental contexts.46–48
Although canonical Wnt signaling was increased upon Ror2 loss,
the phenotypic outcomes of Ror2 depletion were not equivalent
across basal-like TP53-null models. The lack of a consensus Ror2
signature derived from in vivo knockdown experiments reflects
the intertumoral heterogeneity observed between models,
despite the common loss of TP53 and their clustering as basal-
like. Nonetheless, these studies reveal unique functions for Ror2
depending on cell context and evoke a more complicated view of
Wnt pathway integration and signaling downstream of Ror2 in
breast cancer. We suspect that Ror2 loss differentially impacts the
net balance of Wnt signaling within basal-like models to varying
extents, likely dependent on the existing repertoire of Wnt
ligands, receptors, modulators and downstream signaling con-
stituents. In the case of the 2225L TP53-null model, we identified
interesting differences in Wnt receptor and ligand expression
across basal-like and claudin-low subpopulations. Loss of Ror2
expression, if coupled to other receptors, could release Wnt
receptor availability of Fzd to engage other co-receptors, allowing
for alterations in signaling output.49 Additionally, changes in Wnt
receptor availability may alter the output of a single Wnt, as has
been shown for Wnt5a.14 Wnt5a, known to signal through Ror2,
exhibits both tumor suppressive and promoting roles in breast
cancer.24,50–54 The combination of Wnt receptors and presence/
absence of Ror2 could provide an explanation for the contrasting
functions previously proposed for Wnt5a. Deciphering these
intricacies is essential to unraveling subtype-specific and more
refined functions for alternative Wnt signaling in breast cancer
progression.
In spite of the absence of a unique gene signature downstream
of Ror2, GO enrichment analysis identified a consistent cell
adhesion and migration program impacted in all three models,
most pronounced within 2225L compared with either T1 or T2.
The presence of altered cell adhesion programs was intriguing,
particularly within 2225L, given the role of non-canonical Wnt
signaling in directing cell movements and polarity decisions.11
Lentiviral silencing of Ror2 in three-dimensional cultures disrupted
cytoskeletal F-actin localization along with proper patterning of
pERM, a linker between the actin cytoskeleton and the plasma
membrane.55,56 The fact that ERM proteins interact with mem-
brane proteins and the actin cytoskeleton to organize membrane-
cytoskeletal-associated complexes suggests Ror2 may be instru-
mental in regulating cytoskeleton remodeling and intercellular
adhesions during tumor progression. Indeed, the pERM landscape
within shRor2 tumors of 2225L was drastically changed
(Supplementary Figures S5a and b), suggesting that non-
canonical Wnt/β-catenin-independent signaling through Ror2 is
integral for proper cytoskeletal and intercellular interactions
among tumor cells.57 Moreover, ERM proteins have been strongly
implicated in orchestrating metastatic potential in multiple
cancers.58,59 In three-dimensional culture, we identified an
impaired Dvl2→ RhoA→ ROCK1→ JNK pathway downstream of
Ror2 silencing, accompanied by disruption in organoid integrity
and enhanced migratory capability. ROCK1 inhibition phenocop-
ied the loss of Ror2 in vitro, implicating ROCK signaling
downstream of Ror2 in guiding cellular adhesions in vivo. Several
studies now demonstrate the importance of the Rho pathway in
mediating adhesion and migration cues within the tumor
microenvironment, likely cancer- and cell-type dependent.60
Akin to their normal tissue counterpart, breast cancers harbor
subpopulations of cells composed of a hierarchy, representing
various states of cellular differentiation.6,61 These states of cellular
differentiation are reflected within and across breast cancer
intrinsic subtypes and offer significant insights into the cellular
composition and molecular makeup of a given tumor. Within
these cellular landscapes, the coexistence of subpopulations likely
involves paracrine and collaborative interactions that provide a
supportive function during tumor progression.62,63 Here, we
identified a bulk basal-like and minor claudin-low subpopulation
within the genomically classified basal-like TP53-null model,
2225L, where Ror2 regulated the proportion of these subpopula-
tions in vivo. Of note, basal-like and claudin-low subtypes possess
very similar genomic features that mirror luminal progenitor and
bi-potent mammary stem cells, respectively, within the normal
breast hierarchy.6 The specific increase in the claudin-low
subpopulation by CD24/CD29 cell surface expression and enrich-
ment in claudin-low-associated genes upon Ror2 loss is intriguing,
given the cell adhesion defects and enhanced migration capacity
of Ror2-depleted tumor cells observed in three-dimensional
organoids. Claudin-low breast cancers possess mesenchymal and
stem cell-associated features and lack tight junction proteins,4,7,40
properties associated with conveying metastatic potential within
breast and other solid tumors. Moreover, claudin-low signatures
have been identified in residual tumor tissue after either
endocrine or chemotherapy.64 Although triple negative breast
cancers exhibit a pathological complete response (pCR) of 30–
40%,65,66 plasticity from basal-like to claudin-low states, as
observed upon Ror2 depletion, may be an important factor with
regard to clinical response and treatment resistance.
Thus, our data couple cell adhesion defects with alterations in
cell state plasticity within 2225L breast tumor models downstream
of Ror2 loss. The alternative Wnt receptor, Ror2, therefore, might
not only provide a spatial constraint for canonical Wnt signaling
topology, but may also restrain the potential of tumor cells to
migrate and intravasate within the context of a heterogeneous
tumor landscape. Computational models now show the impact of
short-range dispersal and cell turnover on cell mixing within a
tumor, responsible for the regulation of intratumoral heterogene-
ity, metastatic potential and treatment resistance.67 The identifica-
tion of these subpopulations and the regulation of their
coexistence within the tumor, beyond Wnt signaling, are therefore
both biologically and clinically important.
MATERIALS AND METHODS
Mouse strains, TP53null transplant lines and maintenance
This study was performed in accordance with the rules of the Guide for the
Care and Use of Laboratory Animals of the NIH. All mice were maintained
and killed according to guidelines of our institutional IACUC (Protocol
AN-504). Balb/c inbred female mice (strain #047, 3–4 weeks of age) were
purchased from ENVIGO (Houston, TX, USA) and used to propagate the
TP53-null tumors. TP53-null mammary tumors were previously generated
by transplantation of donor mammary epithelium from Balb/c mice, where
TP53 was deleted from the germline, into syngeneic hosts for derivation of
TP53-null mammary tumors.30,31 Subsequent mammary tumors were
maintained and propagated in the mouse as a transplantable bank of
TP53-null tumors representative of breast cancer subtypes.
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Lentiviral plasmids
Lentiviral LeGO plasmids68 and shRNA and ORF sequences for Ror2 were
derived and validated as described.34 Wnt pathway reporters32 (Addgene,
plasmids 7TGC, 7TG and 7TF #24304, #24314 and #24306, Cambridge, MA,
USA) were validated in mammary epithelial cells as described.34
Tumor cell isolation
Primary TP53-null tumor cells were isolated similarly to normal primary
mammary epithelial cells.34 Digests were subjected to a series of short
centrifugation steps (8 s × 1500 r.p.m.) to enrich for tumor organoids.
Organoids were subjected to 0.05% trypsin at 37 °C for 5 min, washed and
filtered through a 0.40-μm cell strainer to obtain single cells. Single cells
were washed 2× with phosphate-buffered saline.
Lentiviral transduction of primary TP53-null tumor cells
Transduction of primary TP53-null tumor cells was performed as
described,34 with modifications. Single tumor cells were seeded (500 000
cells/well) in a 24-well plate and infected at an MOI of 30 with lentivirus in
growth media. Cells were infected overnight and were then washed with
phosphate-buffered saline and resuspended in a 1:1 ratio of growth factor-
reduced Matrigel/HBSS at 25 000 cells/10 μl injection volume.
Fluorescence-activated cell sorting staining and analysis
Lineage-positive cells were depleted from single-cell preparations using
the EasySep Mouse Mammary Stem Cell Enrichment kit (#19757; Stemcell
Technologies, Vancouver, BC, Canada). For transduced tumors, tdTomato
fluorescence was used to positively select Lin− tumor cells for analysis and
sorting. Single-cell preparations were resuspended (107 cells/ml in HBSS+
(containing 2% fetal bovine serum with 10 mM HEPES buffer)) for antibody
staining. Antibody incubations were performed on ice for 30 min. Cells
were stained with anti-mouse CD24-Pacific Blue and anti-mouse CD29-APC
(1:100; BioLegend, San Diego, CA, USA). Cells were either fluorescence-
activated cell sorting analyzed (LSR Fortessa; BD Biosciences, Franklin
Lakes, NJ, USA) or sorted (Aria II; BD Biosciences). Data analysis was
performed using FlowJo, version 9.5.3 (Tree Star, Ashland, OR, USA).
Tumor organoids assays
Lineage-depleted tumor cells were transduced as described above. Eight-
well chamber slides were coated with growth factor-reduced Matrigel
(5 μl). Aggregated organoids were washed in phosphate-buffered saline
before suspending in growth factor-reduced Matrigel at 50 000 cells/40 μl.
Within each chamber, 40 μl of cell suspension was plated and solidified at
37 °C for 30 min. Cultures were overlaid with 500 μl of growth media. For
western blots, organoids were retrieved with matrigel recovery solution
(#354253; Corning) and washed prior to lysis with RIPA buffer.
RNA isolation and gene expression profiling
Total RNA was purified from 20 to 30 mg of mouse mammary tumors or
sorted samples (tdTomato+) following the manufacturer's protocol
(#74104; Qiagen, Germantown, MD, USA). The BCM Genomic and RNA
Profiling Core performed sample quality checks using the Nanodrop ND-
1000 (ThermoFisher Scientific, Waltham, MA, USA) and a Bioanalyzer Nano
chip (Agilent Technologies, Santa Clara, CA, USA). Murine TP53-null
mammary tumors were microarray profiled as previously described69 and
uploaded to the gene expression omnibus (GEO) under accession number
GSE93815. RNA was reverse transcribed and labeled with cyanine-5 (Cy5)
dye for experimental samples and cyanine-3 (Cy3) dye for mouse reference
samples70 using Agilent Low RNA Input Fluorescent Linear Amplification
Kit. Equal quantities of labeled mouse reference and tumor RNA were co-
hybridized overnight to custom Agilent microarrays, washed, scanned and
signal intensities determined. Top differential genes found for any of the
three models (Po0.01 by t-test using log-transformed data, fold change
41.4) were clustered, using a supervised approach.71 Breast cancer gene
expression profiles from TCGA were scored for a previously reported Wnt
signature,72 by first normalizing expression values to standard deviations
from the median across tumor profiles, then applying our previously
described t-score metric.73 Enriched GO terms within gene sets was
assessed using Sigterms.74 Gene expression signatures were created by
performing a two-class (shRor2 vs shLuc) Significance Analysis of
Microarrays (SAM) analysis on the microarray data set.75 Signatures in
Figure 4f were defined as all genes either highly or lowly expressed
with a false discovery rate o5%. Expression scores for each gene
signature were determined by calculating the standardized median
expression of the signature within each sample of the UNC308 human
breast cancer data set.7
Quantitative real-time PCR
Quantitative real-time PCR was performed using SYBR green methodology
(Applied Biosystems, Foster City, CA, USA). Primer sequences
(Supplementary Table S1) were designed using the Roche Universal Probe
Library. Relative gene expression changes were determined after normal-
izing to β-actin and calculating the ΔΔCT. s.d. calculations were performed
on fold changes observed among biological replicates, derived from the
calculated 2−ΔΔCt.
Processing of tumors tissue and organoids cultures
Mice were administered 60 μg/g body weight BrdU via intraperitoneal
injection 2 h before killing. Tumors were dissected and fixed in 4%
paraformaldehyde overnight at 4 °C before processing to paraffin blocks.
Organoid cultures were washed with phosphate-buffered saline and fixed
in 4% paraformaldehyde (10 min) before processing to paraffin block or
staining with Phalloidin (#A12379; ThermoFisher Scientific).
Immunostaining and western blotting
Tissue and organoid sections were deparaffinized, rehydrated and
subjected to Tris-EDTA antigen retrieval for 20 min in a microwave.
Primary antibodies were applied overnight at 4 °C. Antibodies and
concentrations were: Ror2 (1:100; Nt 2535-2835, Ror2-s; Developmental
Studies Hybridoma Bank, Iowa City, IA, USA), eGFP (1:250; ab290; Abcam,
Cambridge, MA, USA), K8 (1:250; TROMA-1; Developmental Studies
Hybridoma Bank), K5 (1:5,000; PRB-160P; Covance, Princeton, NJ, USA),
BrdU (1:250; ab6326; Abcam), CC3 (1:200; 9661; Cell Signaling Technology
(CST), Danvers, MA, USA) and pERM (1:500; CST). Tyramide amplification
was performed for Ror2 detection according to the manufacturer's
instructions (NEL701A001KT; PerkinElmer, Waltham, MA, USA). For western
blotting, the following antibodies were used: Ror1 (1:1000, #4102; CST),
Dvl2 (1:1000, #3216; CST), RhoA (1:1000, #2117; CST), Rac1/2/3 (1:1000,
#2465; CST), CDC42 (1:1000, #2466; CST), c-jun (1:1000, #9265; CST), p-c-jun
s63 (1:1000, #9261; CST).
Microscope image acquisition
Sample preparation and microscope image acquisition were carried out as
previously described.34
Statistical analysis
Unpaired two-tailed Student’s t-tests were performed on analyses
involving two-group comparisons unless otherwise noted. Quantitative
measurements were performed in ImageJ or Excel (Microsoft; *Po0.05;
**Po0.01; ***Po0.001). Plotted values represent means ± s.d. In all cases,
experiments were reproduced across multiple (3) experiments.
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